Zentalis Pharmaceuticals Llc Stock Net Asset
| ZNTL Stock | USD 1.34 0.04 2.90% |
Fundamental analysis of Zentalis Pharmaceuticals allows traders to better anticipate movements in Zentalis Pharmaceuticals' stock price by examining its financial health and performance throughout various phases of its business cycle.
Zentalis | Net Asset | Build AI portfolio with Zentalis Stock |
Zentalis Pharmaceuticals Llc Company Net Asset Analysis
Zentalis Pharmaceuticals' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Zentalis Pharmaceuticals Net Asset | 430.34 M |
Most of Zentalis Pharmaceuticals' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Zentalis Pharmaceuticals Llc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Zentalis Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Zentalis Pharmaceuticals is extremely important. It helps to project a fair market value of Zentalis Stock properly, considering its historical fundamentals such as Net Asset. Since Zentalis Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Zentalis Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Zentalis Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Zentalis Total Assets
Total Assets |
|
Based on the recorded statements, Zentalis Pharmaceuticals Llc has a Net Asset of 430.34 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Zentalis Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Zentalis Pharmaceuticals' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Zentalis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Zentalis Pharmaceuticals by comparing valuation metrics of similar companies.Zentalis Pharmaceuticals is currently under evaluation in net asset category among its peers.
Zentalis Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Zentalis Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Zentalis Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Zentalis Pharmaceuticals' value.| Shares | Primecap Management Company | 2025-03-31 | 1.3 M | Bank Of America Corp | 2025-03-31 | 1.1 M | D. E. Shaw & Co Lp | 2025-03-31 | 1.1 M | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 1.1 M | Tybourne Capital Management (hk) Ltd | 2025-03-31 | 961.5 K | Pfizer Inc | 2025-03-31 | 953.8 K | Two Sigma Advisers, Llc | 2025-03-31 | 842.6 K | Renaissance Technologies Corp | 2025-03-31 | 826 K | Federated Hermes Inc | 2025-03-31 | 752.5 K | Matrix Capital Management Company, Llc | 2025-03-31 | 14 M | Blackrock Inc | 2025-03-31 | 4.2 M |
Zentalis Fundamentals
| Return On Equity | -0.59 | ||||
| Return On Asset | -0.27 | ||||
| Operating Margin | (7.46) % | ||||
| Current Valuation | (193.79 M) | ||||
| Shares Outstanding | 71.95 M | ||||
| Shares Owned By Insiders | 13.57 % | ||||
| Shares Owned By Institutions | 80.99 % | ||||
| Number Of Shares Shorted | 4.77 M | ||||
| Price To Book | 0.34 X | ||||
| Price To Sales | 3.70 X | ||||
| Revenue | 67.42 M | ||||
| Gross Profit | 26.86 M | ||||
| EBITDA | (191.19 M) | ||||
| Net Income | (165.87 M) | ||||
| Cash And Equivalents | 455.22 M | ||||
| Cash Per Share | 7.99 X | ||||
| Total Debt | 39.58 M | ||||
| Debt To Equity | 0.1 % | ||||
| Current Ratio | 9.61 X | ||||
| Book Value Per Share | 4.11 X | ||||
| Cash Flow From Operations | (170.86 M) | ||||
| Short Ratio | 3.37 X | ||||
| Earnings Per Share | (3.14) X | ||||
| Target Price | 6.86 | ||||
| Number Of Employees | 166 | ||||
| Beta | 1.6 | ||||
| Market Capitalization | 99.29 M | ||||
| Total Asset | 430.34 M | ||||
| Retained Earnings | (1.05 B) | ||||
| Working Capital | 333.34 M | ||||
| Net Asset | 430.34 M |
About Zentalis Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Zentalis Pharmaceuticals Llc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zentalis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zentalis Pharmaceuticals Llc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Zentalis Pharmaceuticals Piotroski F Score and Zentalis Pharmaceuticals Altman Z Score analysis. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.